ohm: Your comment to Respert that MRK should just buy out
ohm: Your comment to Respert that MRK should just buy out CYDY, get LL approved, and move on from Keytruda is exactly what I have been thinking while diving into the LL/Keytuda CRC clinical trial conjecture and discussion on the board these last few days. Given your assessments that the LL/K combo would be neither synergistic nor capable of extending Keyrtuda's looming 4 year patent cliff, why wouldn't MRK just adopt the Green Bay Packers successful strategy of drafting Aaron Rodgers and then developing him for 3 years while Brett Favre moves through the twilight of his HOF career? MRK doesn't need to extend Keytruda when it can buy at an even better drug with plenty of patent life at a reasonable discount to replace Keytruda by the time the cliff is reached.
Notwithstanding the above, I have seen nothing to support the notion that MRK is pursuing a BO of CYDY. And even the prospect of a MRK/CYDY partnership for oncology indications would be conjectural at best. But it is mind-boggling to me that given Keytruda's patent cliff situation and MRK's many recent clinical trial failures to find a combo drug to extend the patent, that MRK has not become aggressive in pursuing LL in one way or another. Given the LL/Keytruda mouse study, it seems inconceivable that MRK would not be aware of the role of CCR5 in facilitating metastasis in so many lethal conditions and LL's singular ability to block CCR5 from doing such damage.
As you and others have pointed out, NIH funding, if it becomes available, may be the best pathway for CYDY to commercialize LL. But while that pathway has the potential to eventually generate a very high sp, it will also involve far greater risks for ultimate LL approval and the sp than a BO at a reasonable discount against potential value.
If MRK management ever wakes up and acts accordingly, I would welcome the shareholder debate over these alternative pathways.
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...
Continue Reading
Shaking Up Estate Planning: Quorum Joins LIVE Coalition Here's a fresh shake-up in the world of estate planning. Quorum Federal Credit Union has thrown its hat into the ring as the latest member of the LIVE Coalition, a band of financial, legal, and tech wizards putting estate plans on a modern track. This marks them as the 70th player to dive into this alliance, pushing...
Continue Reading
Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...
Continue Reading
Reimagining Pizza with Wisconsin's Best Cheeses It's not every day you see a pizza challenge that turns a staple of Friday nights into a gastronomic showcase. But that's exactly what's happening in Wisconsin as chefs flex their creativity using Crave Brothers Farmstead Cheese. This is no ordinary cheese-and-pepperoni affair—these culinary pros are cooking up pizzas with...
Continue Reading
Hyundai's Drive to Record Q3 Sales When talking about market moves, Hyundai's recent figures speak louder than most quarterly bells. September 2026 marked a whirlwind of growth for Hyundai Motor America, reporting record-breaking sales numbers not just for the month, but for Q3 as a whole. With a 9% jump from September last year in total vehicle sales and a remarkable 3%...
Continue Reading
Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...
Continue Reading
A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...
Continue Reading
Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...
Continue Reading
Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...
Continue Reading
The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...
Continue Reading
Top 5 Most Recently Viewed Articles
Alkermes (NASDAQ: ALKS) found itself in the spotlight back in early 2024 when Mizuho backed the company with an Outperform rating and held firm on a price target of $35.00. This wasn’t just fluff; it came hot on the heels of some fresh data from Takeda shared at the SLEEP Europe conference, showcasing their drug TAK-861, which was in Phase 2 trials for narcolepsy type 1...
Continue Reading
Investigation into Steelcase Inc.'s Deal for Shareholders The Ademi Firm is conducting an important investigation regarding Steelcase (NYSE: SCS) aimed at uncovering whether the company is providing a fair deal for its public shareholders amid its recent sale transaction with HNI Corporation. Details of the Transaction Shareholders of Steelcase are poised to receive $7.20...
Continue Reading
Raytheon's New Missile Plant Signifies A Transformative Moment R2S Inc., a collaboration between Raytheon Technologies Corporation (NYSE: RTX) and Rafael Advanced Defense Systems Ltd., is embarking on a significant venture by launching a missile interceptor production facility. This strategic development involves a substantial $1.25 billion contract focused on producing...
Continue Reading
The average rate for a 30-year fixed-rate mortgage (FRM) dropped to 6.08 percent, the lowest level in two years according to Freddie Mac’s latest report from early 2024. Traders were already buzzing about the implications this had on refinancing options and the overall housing market trajectory. Mortgage Rates Shift: What It Means for Homeowners This drop from last...
Continue Reading
The Launch of Glemaud x Tura Men's Eyewear Collection Bold Design Meets Tailored Comfort Renowned knitwear designer Victor Glemaud, alongside the celebrated NYC eyewear house Tura, is thrilled to unveil the highly anticipated Glemaud x Tura Men's Eyewear Collection. This launch enriches their previously successful women's line, which debuted a few years ago. Their goal...
Continue Reading